Walpar Nutritions IPO is all set to make its debut on 30th June 21 with 5.13 Cr manufactures different types of Nutraceuticals, Ayurvedic, Cosmeceuticals, Sexual Wellness, and food supplement products.
Walpar Nutritions IPO – overview
| IPO Dates | 30th June – 5th July 2021 |
| IPO Price | INR 55 per share |
| Fresh issue | – |
| Offer For Sale | Nil |
| Total IPO size | 1,200,000 shares (INR 6.60 crore) |
| Minimum bid (lot size) | 2000 shares |
| Face Value | INR 10 per share |
| Retail Allocation | 50% |
| Listing On | NSE Emerge |
Walpar Nutritions IPO – Tentative Dates
| IPO Offer Opening Date | 27 July 2021 |
| IPO Closing Date | 30 July 2021 |
| Finalization of Basis of Allotment | 4 Aug 2021 |
| Initiation of refunds | 5 Aug 2021 |
| Transfer of shares to demat accounts | 6 Aug 2021 |
| IPO Listing Date | 9 Aug 2021 |
| Opening Price on NSE SME | Coming soon |
| Closing Price on NSE SME | Coming soon |
Company Overview
Incorporated in 2009, Walpar Nutritions manufactures different types of Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness, and food supplement products.
The company has a manufacturing facility in Gandhinagar with an installed manufacturing capacity of 23 lakhs tablet/month, 12.50 lakhs capsules/month, 1.50 lakhs oral liquids/month, and 2 lakhs sachets/month.
Industry Overview
India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. India enjoys an important position in the global pharmaceuticals sector. Pharmaceuticals export from India stood at US$ 16.3 billion in FY20. Pharmaceutical export includes bulk drugs, intermediates, drug formulations, biologicals, Ayush and herbal products and surgical. As of October 2020, India exported pharmaceuticals worth US$ 13.87 billion in FY21. Pharmaceutical exports from India stood at US$ 16.28 billion in FY20 and US$ 2.07 billion in October 2020.
Competitive Strengths:
- Large product portfolio with 70+ products.
- Strong product manufacturing and development capabilities.
- Best quality products, certified by FSSAI and AYUSH department.
Objectives of the issue
- To invest in subsidiaries.
- Meet working capital requirements.
- Meet general corporate purposes.
- Meet issue expenditures.
Company Financials
| Particulars | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 |
| Total Assets | 1,317.41 | 918.09 | 390.37 |
| Total Revenue | 1,671.27 | 1,282.27 | 644.53 |
| Profit After Tax | 12.18 | 6.88 | 0.33 |
Company Contact Information
Walpar Nutritions Limited
2nd Floor, L5: 377 PLOT:5, Opp. Sabarmati, Village
Taluka kalol, Gandhinagar-382721
Phone: +91 94277 12047
Email: finance.walpar@hotmail.com
Website: http://www.walparnutritions.com/
Registrar
Skyline Financial Services Private Ltd
Phone: 02228511022
Email: compliances@skylinerta.com
Website: https://www.skylinerta.com/
Lead Manager(s)
- Beeline Broking Ltd (Past IPO Performance)
Lead Manager Reports
- IPO Lead Manager Performance Summary
- IPO Lead Manager Performance Tracker
